|
|
||||||||
VASCULAR BIOLOGY
1Instituto de Investigaciones Médicas, Fundación Jiménez Díaz; 4Universidad Autónoma de Madrid, and 2Instituto Reina Sofía de Investigación Nefrológica, 28040 Madrid, Spain; and 3Molecular and Cell Biology Department, Imclone Systems Incorporated, New York, New York 10014
Submitted 17 July 2003 ; accepted in final form 23 December 2003
Proangiogenic, proliferative effects of tumors have been extensively characterized in subconfluent endothelial cells (EC), but results in confluent, contact-inhibited EC are critically lacking. The present study examined the effect of tumor-conditioned medium (CM) of the malignant osteoblastic cell line MG63 on monolayer, quiescent bovine aorta EC. MG63-CM and MG63-CM + CoCl2 significantly increased EC survival in serum-starved conditions, without inducing EC proliferation. Furthermore, MG63-CM and MG63-CM + CoCl2, both containing high amounts of vascular endothelial growth factor (VEGF), induced relevant phenotypic changes in EC (all P < 0.01) involving increase of nucleoli/chromatin condensations, nucleus-to-cytosol ratio, capillary-like vacuolated structures, vessel-like acellular areas, migration through Matrigel, growth advantage in reseeding, and factor VIII content. All these actions were significantly inhibited by VEGF and VEGF receptor (VEGFR2) blockade. Of particular importance, a set of similar effects were detected in a human microvascular endothelial cell line (HMEC). With regard to gene expression, incubation with MG63-CM abolished endogenous VEGF mRNA and protein but induced a clear-cut increase in VEGFR2 mRNA expression in EC. In terms of mechanism, MG63-CM activates protein kinase B (PKB)/Akt, p44/p42-mitogen-activated protein kinase (MAPK)-mediated pathways, as suggested by both inhibition and phosphorylation experiments. In conclusion, tumor cells activate confluent, quiescent EC, promoting survival, phenotypic, and gene expression changes. Of importance, VEGF antagonism converts MG63-CM from protective to EC-damaging effects.
vascular endothelial growth factor receptor 2; MG63-conditioned medium
This article has been cited by other articles:
![]() |
F. Neria, C. Caramelo, H. Peinado, F. R. Gonzalez-Pacheco, J. JP. Deudero, A. J. de Solis, R. Fernandez-Sanchez, S. Penate, A. Cano, and M{a} A. Castilla Mechanisms of endothelial cell protection by blockade of the JAK2 pathway Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1123 - C1131. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. N. Younes, Y. W. Park, Y. D. Yazici, M. Gu, A. A. Santillan, X. Nong, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol. Cancer Ther., November 1, 2006; 5(11): 2696 - 2705. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. R. Gonzalez-Pacheco, J. J. P. Deudero, M. C. Castellanos, M. A. Castilla, M. V. Alvarez-Arroyo, S. Yague, and C. Caramelo Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2 Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1395 - H1401. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |